Sarcopenia Impact Among Older Patients With Newly Diagnosed Multiple Myeloma

Overview

About this study

The purpose of this study is to evaluate the association between baseline sarcopenia and high-grade chemotherapy toxicity during the first 4 cycles of treatment measured by National Cancer Institute Common Terminology Criteria for Adverse Events (CTCAE) v5.0, the Patient-Reported Outcomes (PRO) version of the CTCAE(PRO-CTCAE), and treatment discontinuation in older patients (≥60 years) with hematologic malignancies.

The hypothesis is that for older patients with hematologic malignanclies, sarcopenia is associated with higher likelihood of high-grade treatment-related chemotherapy toxicity and a higher rate of treatment discontinuation during the first 4 cycles of treatment.

Participation eligibility

Participant eligibility includes age, gender, type and stage of disease, and previous treatments or health concerns. Guidelines differ from study to study, and identify who can or cannot participate. There is no guarantee that every individual who qualifies and wants to participate in a trial will be enrolled. Contact the study team to discuss study eligibility and potential participation.

Inclusion Criteria:

  • Age ≥ 60 years.
  • New diagnosis of MM based on IMWG diagnostic criteria 76.
  • Planned to start a new treatment for MM within 30 days at Mayo Clinic in Rochester, MN. Patients who are receiving chemotherapy at a location other than Mayo Clinic in Rochester, MN but undergoing evaluation prior to each cycle at Mayo Clinic in Rochester, MN are eligible.
  • Transplant eligible or ineligible.
  • Fluent in English (all assessment tools are in English).
  • Able to provide written informed consent.

Exclusion Criteria:

  • Received ≥1 prior line of treatment..
  • Not able to give informed consent.

Eligibility last updated 9/22/22. Questions regarding updates should be directed to the study team contact.

Participating Mayo Clinic locations

Study statuses change often. Please contact the study team for the most up-to-date information regarding possible participation.

Mayo Clinic Location Status Contact

Rochester, Minn.

Mayo Clinic principal investigator

Shaji Kumar, M.D.

Closed for enrollment

Contact information:

Sarah Aug

5075381301

aug.sarah@mayo.edu

More information

Publications

Publications are currently not available

Additional contact information

Cancer-related trials contact form

Phone: 855-776-0015 (toll-free)

International patient clinical studies questions